European Biotechnology wrote that although the European stock markets are registering a boom, some biotechs still feel safer in the tried-and-tested US waters. Danish clinical stage biopharma company Ascendis Pharma has successfully raised US$108m (€95.5) by offering 6 million shares at US$18 (€16m). The Copenhagen-based company can be pleased with the result – initially they had offered only 5 million shares, with a price range of US$16 to US$18. Ascendis will trade under the ticker symbol “ASND.”
Meanwhile, Irish biotech Nexvet has announced the terms for its own IPO on the other side of the Atlantic. The Dublin-based clinical-stage biopharmaceutical company develops therapeutic monoclonal antibodies for pets. Nexvet also plans to list on NASDAQ and wants to raise US$58m (€51m), with each of the 4 million shares offered for US$13 to US$16 (€11.5 to €14.1).
Continuing the recent rush of European stock markets listings, Liverpool-based Redx Pharma announced this week it would be staying this side of the pond for its €105m initial public offering: the drug developer aims to float on the London Stock Exchange AIM.